YU1901A - Pharmaceutical uses for nab1 and nab2 - Google Patents

Pharmaceutical uses for nab1 and nab2

Info

Publication number
YU1901A
YU1901A YU1901A YU1901A YU1901A YU 1901 A YU1901 A YU 1901A YU 1901 A YU1901 A YU 1901A YU 1901 A YU1901 A YU 1901A YU 1901 A YU1901 A YU 1901A
Authority
YU
Yugoslavia
Prior art keywords
nab1
nab2
pharmaceutical uses
polypeptides
mammal
Prior art date
Application number
YU1901A
Other languages
Serbo-Croatian (sh)
Inventor
Martin Braddock
Callun Jeffrey Campbell
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of YU1901A publication Critical patent/YU1901A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use, particularly in gene therapy, of an NAB1 or NAB2 polypeptide or a biologically active fragment thereof, and to nucleic acid molecules encoding such polypeptides, in the manufacture of a medicament for the treatment of cell proliferation disorders associated with wound healing in a mammal, including human.
YU1901A 1998-07-11 1999-07-09 Pharmaceutical uses for nab1 and nab2 YU1901A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method

Publications (1)

Publication Number Publication Date
YU1901A true YU1901A (en) 2005-06-10

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1901A YU1901A (en) 1998-07-11 1999-07-09 Pharmaceutical uses for nab1 and nab2

Country Status (22)

Country Link
EP (1) EP1097200A1 (en)
JP (1) JP2002520020A (en)
KR (1) KR20010071832A (en)
CN (1) CN1317045A (en)
AP (1) AP2001002038A0 (en)
AU (1) AU763713B2 (en)
BR (1) BR9912018A (en)
CA (1) CA2336805A1 (en)
EA (1) EA200100028A1 (en)
EE (1) EE200100020A (en)
HR (1) HRP20010025A2 (en)
HU (1) HUP0102835A3 (en)
ID (1) ID27742A (en)
IL (1) IL140533A0 (en)
IS (1) IS5788A (en)
NO (1) NO20010166L (en)
NZ (1) NZ509174A (en)
PL (1) PL345507A1 (en)
SK (1) SK382001A3 (en)
TR (1) TR200100622T2 (en)
WO (1) WO2000003014A1 (en)
YU (1) YU1901A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
CN1317045A (en) 2001-10-10
IS5788A (en) 2000-12-22
AU763713B2 (en) 2003-07-31
IL140533A0 (en) 2002-02-10
KR20010071832A (en) 2001-07-31
AP2001002038A0 (en) 2001-03-31
NZ509174A (en) 2003-08-29
TR200100622T2 (en) 2001-10-22
SK382001A3 (en) 2001-09-11
EA200100028A1 (en) 2001-08-27
AU4791499A (en) 2000-02-01
NO20010166D0 (en) 2001-01-10
WO2000003014A1 (en) 2000-01-20
EE200100020A (en) 2002-06-17
HUP0102835A3 (en) 2003-09-29
CA2336805A1 (en) 2000-01-20
EP1097200A1 (en) 2001-05-09
NO20010166L (en) 2001-03-06
PL345507A1 (en) 2001-12-17
HUP0102835A2 (en) 2001-11-28
ID27742A (en) 2001-04-26
JP2002520020A (en) 2002-07-09
HRP20010025A2 (en) 2001-12-31
BR9912018A (en) 2006-01-31

Similar Documents

Publication Publication Date Title
DE69630890D1 (en) PEPTID-IMITATING SUBSTANCES IN CANCER THERAPY
NO20024157D0 (en) Casein-derived peptides and their applications in therapy
NZ500657A (en) Interleukin-3 gene therapy for cancer
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
FI955552A (en) Adenoviral vectors of animal origin and their use in gene therapy
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
AP2000001999A0 (en) Gene therapy method.
WO2004034966A3 (en) Substances for preventing and treating autoimmune diseases
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
NZ500427A (en) The use of ribozyme treatment for retinal diseases
ES2181710T3 (en) ADENOVIRUS RECOMBINANTS AND ITS USE IN GENE THERAPY FOR THE TREATMENT OF EYE PATHOLOGIES.
BG106051A (en) MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING
IL145514A0 (en) Akt nucleic acids, polypeptides, and uses thereof
ATE281159T1 (en) USE OF AMINO ACID IN THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF INSULIN RESISTANCE
YU1901A (en) Pharmaceutical uses for nab1 and nab2
MXPA05004973A (en) Pain relief agents.
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
AU6349400A (en) Methods for treatment of hyperproliferative diseases using human mda-7
WO2002090552A3 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
KR100488038B1 (en) New bpc peptide salts with organo-protective activity the process for their preparation and their use in therapy
UA66749C2 (en) Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases
CA2601208A1 (en) Method of preventing or treating type 1 diabetes by gene therapy with a secreted form of glutamic acid decarboxylase.
WO2002083060A3 (en) Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs